KKPCF Stock Chart & Stats
$23.65
-$2.42(-8.28%)
At close: 4:00 PM EST
$23.65
-$2.42(-8.28%)
Day’s Range― - ―
52-Week Range$20.68 - $30.84
Previous CloseN/A
Volume100.00
Average Volume (3M)0.00
Market Cap
$859.21M
Enterprise Value$103.04B
Total Cash (Recent Filing)$55.40B
Total Debt (Recent Filing)$3.85B
Price to Earnings (P/E)68.6
Beta0.31
Next Earnings
Aug 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield4.34%
Share Statistics
EPS (TTM)333.12
Shares Outstanding44,139,730
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.87
Price to Book (P/B)1.06
Price to Sales (P/S)2.04
P/FCF Ratio-11.15
Enterprise Value/Market Cap119.92
Enterprise Value/Revenue1.09
Enterprise Value/Gross Profit1.77
Enterprise Value/Ebitda5.06
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.59
Revenue Forecast (FY)$495.90M
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetKaken's very low leverage and large equity base provide durable financial flexibility. A conservative balance sheet cushions the company during revenue or cash-flow shocks, supports continued R&D funding or opportunistic M&A, and reduces default risk versus peers over the medium term.
Specialist Dermatology FocusA focused specialty franchise in dermatology supports durable demand and deeper clinical relationships with prescribers. Selling branded drugs through Japan's NHI and established distribution channels creates predictable reimbursement dynamics and structural market access for core products.
Prior Strong Cash Generation & DividendHistorically strong FCF and a meaningful dividend signal the business can generate shareholder cash in normal operating years. This track record supports continued investment in pipeline and the credibility of shareholder distributions if cash generation normalizes.
Bears Say
Sharp Revenue And Margin DeclineA near-20% revenue drop and collapse in operating margins materially weaken the firm's earnings foundation. Sustained top-line pressure reduces internal funding for R&D and commercialization, forcing restructuring or repricing decisions that can impair medium-term growth and competitive positioning.
Material Negative Cash FlowTurnaround to negative operating and free cash flow raises execution and liquidity risk. If cash generation does not recover, management may need to cut R&D, halt launches, reduce dividends, or use balance-sheet resources, which would constrain long-term pipeline investment and growth.
Earnings Volatility And Weakening ReturnsA sharp drop in ROE and steep EPS decline indicate volatile earnings quality. Persistent earnings instability undermines reinvestment capacity and investor confidence, complicates long-term planning, and raises the bar for management to demonstrate sustained recovery in profitability.
Kaken Pharmaceutical Co News
KKPCF FAQ
What was Kaken Pharmaceutical Co Ltd’s price range in the past 12 months?
Kaken Pharmaceutical Co Ltd lowest stock price was $20.68 and its highest was $30.84 in the past 12 months.
What is Kaken Pharmaceutical Co Ltd’s market cap?
Kaken Pharmaceutical Co Ltd’s market cap is $859.21M.
When is Kaken Pharmaceutical Co Ltd’s upcoming earnings report date?
Kaken Pharmaceutical Co Ltd’s upcoming earnings report date is Aug 07, 2026 which is in 21 days.
How were Kaken Pharmaceutical Co Ltd’s earnings last quarter?
Kaken Pharmaceutical Co Ltd released its earnings results on May 13, 2026. The company reported $0.122 earnings per share for the quarter, missing the consensus estimate of $0.123 by -$0.002.
Is Kaken Pharmaceutical Co Ltd overvalued?
According to Wall Street analysts Kaken Pharmaceutical Co Ltd’s price is currently Overvalued.
Does Kaken Pharmaceutical Co Ltd pay dividends?
Kaken Pharmaceutical Co Ltd pays a Semiannually dividend of $0.586 which represents an annual dividend yield of 4.34%. See more information on Kaken Pharmaceutical Co Ltd dividends here
What is Kaken Pharmaceutical Co Ltd’s EPS estimate?
Kaken Pharmaceutical Co Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Kaken Pharmaceutical Co Ltd have?
Kaken Pharmaceutical Co Ltd has 44,139,730 shares outstanding.
What happened to Kaken Pharmaceutical Co Ltd’s price movement after its last earnings report?
Kaken Pharmaceutical Co Ltd reported an EPS of $0.122 in its last earnings report, missing expectations of $0.123. Following the earnings report the stock price went down -1.054%.
Which hedge fund is a major shareholder of Kaken Pharmaceutical Co Ltd?
Currently, no hedge funds are holding shares in KKPCF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Kaken Pharmaceutical Co Ltd
Kaken Pharmaceutical Co., Ltd. is involved in the development, manufacturing, and commercialization of a diverse range of medical goods, health devices, and agricultural chemicals, serving both domestic and global markets. Their extensive product portfolio includes specialized treatments like Clenafin, a topical solution for fungal nail infections; Artz, an agent combating osteoarthritis; Seprafilm, an absorbable film preventing surgical adhesions; Fiblast, a spray designed for pressure and skin ulcer healing; Regroth for periodontal tissue regeneration; and Hernicore, which addresses lumbar disc herniation. They also market Adofeed, a plaster for pain and inflammation relief; Ebrantil for dysuria and hypertension management; Procylin, an oral prostaglandin I2 analogue; Lipidil, used to treat high cholesterol; Mentax, an anti-fungal cream; and Loxoprofen Na Tape, another pain-relieving and anti-inflammatory patch. Additionally, Ropion is offered as an injectable pain medication. The company's agricultural and animal health division provides products such as Polyoxins, a fungicidal agent; Pentoxazone, a herbicide for rice crops; and Salinomycin, an anti-coccidial feed additive for poultry. Kaken Pharmaceutical is actively advancing several investigational compounds. BBI-4000 has completed its Phase III clinical trials for primary axillary hyperhidrosis, while KMW-1 is also in Phase III for managing eschar removal in thermal burns. KAR is being developed for hide lice infestation, and KP-607 is currently in Phase II for the treatment of onychomycosis. Beyond pharmaceuticals, the firm also manages the rental of the commercial property, Bunkyo Green Court. Its products are sold under various brand names, including Mentax Lotrimin Ultra, Mentax Butena, Mentax, Kaifen, Fiblast, and Jublia. The company holds licensing agreements with Corbus Pharmaceuticals Holdings, Inc. and Arbor Pharmaceuticals, LLC. Established in 1917, Kaken Pharmaceutical Co., Ltd. has its main office situated in Tokyo, Japan.
Technical Analysis
Kissei Pharmaceutical Co
―
Towa Pharmaceutical Co
―
Mochida Pharmaceutical Co., Ltd.
―
KYORIN Pharmaceutical Co.,Ltd.
―
SAWAI GROUP HOLDINGS Co., Ltd.
―
Ownership Overview
―
Insiders
3.78% Mutual Funds
― Other Institutional Investors
93.32% Public Companies and
Individual Investors

